There are new treatment options for patients with wet age-related macular degeneration emerging, according to a presentation at Hawaiian Eye 2022. It was a pleasure to speak with Dr Carl Regillo (Thomas Jefferson University, Philadelphia, PA, USA) about his views on the latest treatments to emerge for wet age-related macular degeneration.
The abstract entitled Update on Emerging Wet AMD Therapies was presented at Hawaiian Eye 2022, 15–21 January 2022.
Questions
- What is the current status of the clinical development of tyrosine kinase inhibitors in the treatment of wet age-related macular degeneration? (00:14)
- What other agents are emerging or in late stage clinical development? (02:02)
Speaker Disclosure: Carl Regillo has received speakers’ fees from Genentech, Allergan, Annexon, Novartis, Apellis, Iveric, NGM, Adverum, Regenxbio, Regeneron, Opthea, Thea.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed in coverage of Hawaiian Eye 2022.
